Ann: Race to present at IRD Invest virtual, investor conference, page-48

DrT also mentioned Keytruda which is a Merck oncology drug.

Keytruda (pembrolizumab) for the treatment of advanced melanoma and metastatic non-small-cell lung cancer (NSCLC) in patients whose tumors express PD-L1 with disease progression following other therapies; Emend (aprepitant) for the prevention of chemotherapy-induced and post-operative nausea and vomiting; and Temodar (temozolomide) (marketed as Temodal outside the United States), a treatment for certain types of brain tumors.​

​

Here's the revenue profile for Keytruda (data from annual reports):

• 2015: USD $566M
• 2016: USD $1,402M (YoY 248%)
• 2017: USD $3,809M (YoY 272%)
• 2018: USD $7,171M (YoY 188%)
• 2019: USD $11,084M (YoY 155%)

So that is average annual revenue growth for this new cancer drug 216%, so you can see why handsome sums can be paid for oncology pipelines.

So that gives perspective of revenue potential for an inhibitor treatment.